tiprankstipranks
Cytokinetics (CH:KK3A)
NASDAQ:KK3A
Switzerland Market
KK3A
Cytokinetics
RESEARCH TOOLSreports

Cytokinetics (KK3A) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

KK3A Analyst Ratings

Strong Buy
15Ratings
Strong Buy
13 Buy
2 Hold
0 Sell
Based on 15 analysts giving stock ratings to
Cytokinetics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

KK3A Stock 12 Month Forecast

Average Price Target

$86.66
Based on 15 Wall Street analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $86.66 with a high forecast of $113.16 and a low forecast of $67.09. The average price target represents a ― change from the last price of ―.
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
Highest Price Target$113.16Average Price Target$86.66Lowest Price Target$67.09
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on CH:KK3A
Leonid Timashev
RBC Capital
RBC Capital
CHF96.19→CHF94.57
Buy
―
Reiterated
07/07/26
Cytokinetics price target lowered to $117 from $119 at RBC CapitalCytokinetics price target lowered to $117 from $119 at RBC Capital
Needham Analyst forecast on CH:KK3A
Serge Belanger
Needham
Needham
CHF82.45
Buy
―
Reiterated
06/29/26
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Cytokinetics (NASDAQ: CYTK)
UBS Analyst forecast on CH:KK3A
Ashwani Verma
UBS
UBS
CHF92.96
Buy
―
Upgraded
06/29/26
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (NASDAQ: VRDN) and Cytokinetics (NASDAQ: CYTK)
Mizuho Securities Analyst forecast on CH:KK3A
Salim Syed
Mizuho Securities
Mizuho Securities
CHF80.83→CHF95.38
Buy
―
Reiterated
06/23/26
Mizuho Securities Keeps Their Buy Rating on Cytokinetics (CYTK)
Bank of America Securities Analyst forecast on CH:KK3A
Jason Zemansky
Bank of America Securities
Bank of America Securities
CHF54.16→CHF67.09
Hold
―
Reiterated
06/16/26
Analysts Conflicted on These Healthcare Names: Cytokinetics (NASDAQ: CYTK) and American Well (NYSE: AMWL)
Morgan Stanley Analyst forecast on CH:KK3A
Maxwell Skor
Morgan Stanley
Morgan Stanley
CHF83.26
Buy
―
Reiterated
06/16/26
Analyst Reiterates Buy on Cytokinetics, Citing Aficamten’s Best-in-Class Profile and Safety Edge, Keeps $103 Price Target Unchanged
Citi Analyst forecast on CH:KK3A
Eric Joseph
Citi
Citi
CHF80.02
Buy
―
Reiterated
06/16/26
Cytokinetics Maintained at Buy on Competitive Validation and Differentiation; $99 Price Target Reaffirmed
J.P. Morgan Analyst forecast on CH:KK3A
Tessa Romero
J.P. Morgan
J.P. Morgan
CHF78.41
Buy
―
Reiterated
06/05/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
H.C. Wainwright Analyst forecast on CH:KK3A
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
CHF113.16
Buy
―
Reiterated
05/12/26
Cytokinetics price target raised to $140 from $136 at H.C. WainwrightCytokinetics price target raised to $140 from $136 at H.C. Wainwright
Wells Fargo Analyst forecast on CH:KK3A
Yanan Zhu
Wells Fargo
Wells Fargo
CHF76.79→CHF84.87
Buy
―
Reiterated
05/07/26
Cytokinetics (CYTK) Gets a Buy from Wells Fargo
Raymond James Analyst forecast on CH:KK3A
Unknown Analyst
Raymond James
Not Ranked
Raymond James
―
Hold
―
Reiterated
05/06/26
Raymond James Reaffirms Their Hold Rating on Cytokinetics (CYTK)
Piper Sandler Analyst forecast on CH:KK3A
Yasmeen Rahimi
Piper Sandler
Piper Sandler
CHF86.49
Buy
―
Reiterated
05/06/26
Piper Sandler Reaffirms Their Buy Rating on Cytokinetics (CYTK)
Truist Financial Analyst forecast on CH:KK3A
Srikripa Devarakonda
Truist Financial
Truist Financial
CHF74.36→CHF85.68
Buy
―
Reiterated
05/06/26
Cytokinetics price target raised to $106 from $92 at TruistCytokinetics price target raised to $106 from $92 at Truist
Stifel Nicolaus Analyst forecast on CH:KK3A
James Condulis
Stifel Nicolaus
Stifel Nicolaus
CHF79.21→CHF87.3
Buy
―
Assigned
05/06/26
Cytokinetics price target raised to $108 from $98 at StifelCytokinetics price target raised to $108 from $98 at Stifel
Goldman Sachs Analyst forecast on CH:KK3A
Paul Choi
Goldman Sachs
Goldman Sachs
CHF81.64
Buy
―
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), Strata Critical Medical (NASDAQ: SRTA) and Cytokinetics (NASDAQ: CYTK)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on CH:KK3A
Leonid Timashev
RBC Capital
RBC Capital
CHF96.19→CHF94.57
Buy
―
Reiterated
07/07/26
Cytokinetics price target lowered to $117 from $119 at RBC CapitalCytokinetics price target lowered to $117 from $119 at RBC Capital
Needham Analyst forecast on CH:KK3A
Serge Belanger
Needham
Needham
CHF82.45
Buy
―
Reiterated
06/29/26
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Cytokinetics (NASDAQ: CYTK)
UBS Analyst forecast on CH:KK3A
Ashwani Verma
UBS
UBS
CHF92.96
Buy
―
Upgraded
06/29/26
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (NASDAQ: VRDN) and Cytokinetics (NASDAQ: CYTK)
Mizuho Securities Analyst forecast on CH:KK3A
Salim Syed
Mizuho Securities
Mizuho Securities
CHF80.83→CHF95.38
Buy
―
Reiterated
06/23/26
Mizuho Securities Keeps Their Buy Rating on Cytokinetics (CYTK)
Bank of America Securities Analyst forecast on CH:KK3A
Jason Zemansky
Bank of America Securities
Bank of America Securities
CHF54.16→CHF67.09
Hold
―
Reiterated
06/16/26
Analysts Conflicted on These Healthcare Names: Cytokinetics (NASDAQ: CYTK) and American Well (NYSE: AMWL)
Morgan Stanley Analyst forecast on CH:KK3A
Maxwell Skor
Morgan Stanley
Morgan Stanley
CHF83.26
Buy
―
Reiterated
06/16/26
Analyst Reiterates Buy on Cytokinetics, Citing Aficamten’s Best-in-Class Profile and Safety Edge, Keeps $103 Price Target Unchanged
Citi Analyst forecast on CH:KK3A
Eric Joseph
Citi
Citi
CHF80.02
Buy
―
Reiterated
06/16/26
Cytokinetics Maintained at Buy on Competitive Validation and Differentiation; $99 Price Target Reaffirmed
J.P. Morgan Analyst forecast on CH:KK3A
Tessa Romero
J.P. Morgan
J.P. Morgan
CHF78.41
Buy
―
Reiterated
06/05/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
H.C. Wainwright Analyst forecast on CH:KK3A
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
CHF113.16
Buy
―
Reiterated
05/12/26
Cytokinetics price target raised to $140 from $136 at H.C. WainwrightCytokinetics price target raised to $140 from $136 at H.C. Wainwright
Wells Fargo Analyst forecast on CH:KK3A
Yanan Zhu
Wells Fargo
Wells Fargo
CHF76.79→CHF84.87
Buy
―
Reiterated
05/07/26
Cytokinetics (CYTK) Gets a Buy from Wells Fargo
Raymond James Analyst forecast on CH:KK3A
Unknown Analyst
Raymond James
Not Ranked
Raymond James
―
Hold
―
Reiterated
05/06/26
Raymond James Reaffirms Their Hold Rating on Cytokinetics (CYTK)
Piper Sandler Analyst forecast on CH:KK3A
Yasmeen Rahimi
Piper Sandler
Piper Sandler
CHF86.49
Buy
―
Reiterated
05/06/26
Piper Sandler Reaffirms Their Buy Rating on Cytokinetics (CYTK)
Truist Financial Analyst forecast on CH:KK3A
Srikripa Devarakonda
Truist Financial
Truist Financial
CHF74.36→CHF85.68
Buy
―
Reiterated
05/06/26
Cytokinetics price target raised to $106 from $92 at TruistCytokinetics price target raised to $106 from $92 at Truist
Stifel Nicolaus Analyst forecast on CH:KK3A
James Condulis
Stifel Nicolaus
Stifel Nicolaus
CHF79.21→CHF87.3
Buy
―
Assigned
05/06/26
Cytokinetics price target raised to $108 from $98 at StifelCytokinetics price target raised to $108 from $98 at Stifel
Goldman Sachs Analyst forecast on CH:KK3A
Paul Choi
Goldman Sachs
Goldman Sachs
CHF81.64
Buy
―
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), Strata Critical Medical (NASDAQ: SRTA) and Cytokinetics (NASDAQ: CYTK)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cytokinetics

3 Months
Leonid TimashevRBC Capital
Success Rate
11/16 ratings generated profit
69%
Average Return
+9.56%
Copying Leonid Timashev's trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +9.56% per trade.
1 Year
Joseph PantginisH.C. Wainwright
Success Rate
17/17 ratings generated profit
100%
Average Return
+55.65%
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +55.65% per trade.
2 Years
Joseph PantginisH.C. Wainwright
Success Rate
17/17 ratings generated profit
100%
Average Return
+76.78%
Copying Joseph Pantginis's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +76.78% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KK3A Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
16
12
12
6
5
Buy
20
20
20
24
19
Hold
7
7
6
4
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
43
39
38
34
26
In the current month, KK3A has received 24 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. KK3A average Analyst price target in the past 3 months is 86.66.
Each month's total comprises the sum of three months' worth of ratings.

KK3A Financial Forecast

KK3A Earnings Forecast

Next quarter’s earnings estimate for KK3A is -$1.32 with a range of -$1.63 to -$1.02. The previous quarter’s EPS was -$1.35. KK3A beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year KK3A has Performed in-line its overall industry.
Next quarter’s earnings estimate for KK3A is -$1.32 with a range of -$1.63 to -$1.02. The previous quarter’s EPS was -$1.35. KK3A beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year KK3A has Performed in-line its overall industry.

KK3A Sales Forecast

Next quarter’s sales forecast for KK3A is $13.82M with a range of $6.77M to $22.40M. The previous quarter’s sales results were $15.65M. KK3A beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year KK3A has Performed in-line its overall industry.
Next quarter’s sales forecast for KK3A is $13.82M with a range of $6.77M to $22.40M. The previous quarter’s sales results were $15.65M. KK3A beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year KK3A has Performed in-line its overall industry.

KK3A Stock Forecast FAQ

What is CH:KK3A’s average 12-month price target, according to analysts?
Based on analyst ratings, Cytokinetics’s 12-month average price target is 86.66.
    What is CH:KK3A’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:KK3A, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Cytokinetics a Buy, Sell or Hold?
        Cytokinetics has a consensus rating of Strong Buy, which is based on 13 buy ratings, 2 hold ratings and 0 sell ratings.
          What is Cytokinetics’s share price target?
          The average share price target for Cytokinetics is 86.66. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $113.16 ,and the lowest forecast is $67.09. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Cytokinetics?
            Cytokinetics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
              How can I buy shares of Cytokinetics?
              To buy shares of CH:KK3A, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.